Synthetic Biologics (SYN) Reports Positive Topline Results from Phase 1a Trial of SYN-004
Tweet Send to a Friend
Synthetic Biologics, Inc. (NYSE: SYN) today announced positive topline safety and tolerability results from a Phase 1a clinical trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE